Maternal Immune Activation with the Viral Mimetic Poly:IC in Pregnant Rats.
Animal model
Autism
Cytokine
Development
Maternal infection
Psychiatric illness
Schizophrenia
Journal
Bio-protocol
ISSN: 2331-8325
Titre abrégé: Bio Protoc
Pays: United States
ID NLM: 101635102
Informations de publication
Date de publication:
20 Nov 2020
20 Nov 2020
Historique:
received:
12
01
2020
revised:
24
08
2020
accepted:
31
08
2020
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
5
3
2021
Statut:
epublish
Résumé
Maternal immune activation (MIA) is increasingly well appreciated as an environmental risk factor for some psychiatric disorders. Administration of proinflammatory compounds such as the synthetic double-stranded RNA molecule polyinosinic-polycytidylic acid (polyI:C) to pregnant rodents results in the release of proinflammatory cytokines in the maternal circulation. Various behavioural and brain changes are produced in the offspring that are associated with psychiatric disorders such as autism and schizophrenia. This protocol describes the steps necessary for inducing MIA in pregnant rat dams, which will allow for investigations into the mechanisms in the dam and offspring that mediate the long-term effects of exposure to inflammation while in utero. Increasing our understanding of these mechanisms may provide new insights for the diagnosis, treatment, and prevention of psychiatric disorders. This protocol has been developed and improved over the years by various researchers in Dr. Howland's laboratory at the University of Saskatchewan.
Identifiants
pubmed: 33659469
doi: 10.21769/BioProtoc.3817
pii: e3817
pmc: PMC7842329
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e3817Informations de copyright
Copyright © 2020 The Authors; exclusive licensee Bio-protocol LLC.
Déclaration de conflit d'intérêts
Competing interestsResearch in the Howland laboratory is funded by peer reviewed research grants from government agencies and charities. The authors have no financial or other competing interests to declare.
Références
eNeuro. 2019 Apr 19;6(2):
pubmed: 31016229
eNeuro. 2018 Aug 29;5(4):
pubmed: 30225350
Biol Psychiatry. 2017 Mar 1;81(5):391-401
pubmed: 28137374
Brain Behav Immun. 2017 Jul;63:8-20
pubmed: 27423491
Behav Brain Res. 2011 Oct 10;224(1):180-8
pubmed: 21679729
J Neurosci. 2010 Sep 15;30(37):12424-31
pubmed: 20844137
Brain Behav Immun. 2019 Aug;80:406-418
pubmed: 30980948
J Neurosci. 2003 Jan 1;23(1):297-302
pubmed: 12514227
Physiol Behav. 2013 Feb 17;110-111:73-9
pubmed: 23296084
J Neuroimmunol. 2018 Oct 15;323:87-93
pubmed: 30196839
Science. 2016 Aug 19;353(6301):772-7
pubmed: 27540164
Neuropsychopharmacology. 2019 Jan;44(2):245-258
pubmed: 30188509
Am J Psychiatry. 2018 Nov 1;175(11):1073-1083
pubmed: 30220221
Neurotoxicol Teratol. 2015 Jan-Feb;47:54-65
pubmed: 25450663
Transl Psychiatry. 2017 May 9;7(5):e1120
pubmed: 28485733
Brain Behav Immun. 2019 Nov;82:160-166
pubmed: 31415868
J Psychiatr Res. 2005 May;39(3):311-23
pubmed: 15725430
Pharmacol Ther. 2015 May;149:213-26
pubmed: 25562580
Trends Neurosci. 2019 Nov;42(11):793-806
pubmed: 31493924
J Neurosci. 2006 May 3;26(18):4752-62
pubmed: 16672647
Behav Brain Res. 2014 Jan 1;258:179-86
pubmed: 24129217
Brain Behav Immun. 2014 May;38:175-84
pubmed: 24509090
Behav Brain Res. 2009 Dec 7;204(2):322-34
pubmed: 19154759
Brain Behav Immun. 2008 May;22(4):469-86
pubmed: 18023140
Brain Behav Immun. 2016 Jul;55:25-38
pubmed: 26408796
Prog Neurobiol. 2019 Apr;175:1-19
pubmed: 30590095
Neuropharmacology. 2012 Mar;62(3):1273-89
pubmed: 21703648
Biol Psychiatry. 2019 Jan 15;85(2):107-121
pubmed: 30318336